Humacyte (HUMA) Total Liabilities (2020 - 2026)

Humacyte (HUMA) has 7 years of Total Liabilities data on file, last reported at $98.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $98.9 million, down 21.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.9 million (down 21.8% YoY), and the FY2025 annual result was $113.3 million, down 40.56% from the prior year.
• Total Liabilities slipped to $98.9 million in Q1 2026 per HUMA's latest filing, from $113.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $190.5 million in Q4 2024 and troughed at $87.4 million in Q4 2022.
• A 5-year average of $125.6 million and a median of $113.3 million in 2025 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 830.5% in 2022 and fell as far as 52.73% in 2022.
• A 5-year view of Total Liabilities shows it stood at $87.4 million in 2022, then surged by 31.25% to $114.7 million in 2023, then jumped by 66.15% to $190.5 million in 2024, then slumped by 40.56% to $113.3 million in 2025, then decreased by 12.65% to $98.9 million in 2026.
• Business Quant data shows HUMA's Total Liabilities at $98.9 million in Q1 2026, $113.3 million in Q4 2025, and $96.3 million in Q3 2025.